Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1996 May;110(5):1410-5.
doi: 10.1053/gast.1996.v110.pm8613045.

Botulinum Toxin for Achalasia: Long-Term Outcome and Predictors of Response

Affiliations
Clinical Trial

Botulinum Toxin for Achalasia: Long-Term Outcome and Predictors of Response

P J Pasricha et al. Gastroenterology. .

Abstract

Background & aims: Botulinum toxin injection into the lower esophageal sphincter of patients with achalasia results in effective short-term relief of symptoms. The aims of this study were to examine the long-term outcome of these patients and to determine the predictors of response to this therapy.

Methods: Thirty-one patients with achalasia treated with botulinum toxin were followed up prospectively for a median duration of 890 days.

Results: Twenty-eight patients improved initially, but only 20 patients had sustained improvement beyond 3 months; the latter patients were classified as responders. The response rate was greater in patients older than 50 years of age (82% vs. 43% in younger patients; P = 0.03) and in patients with vigorous achalasia (100% vs. 52% with classic achalasia; P = 0.03). Duration of illness, previous dilation, and baseline radiological characteristics did not influence outcome. Nineteen responders eventually had relapse after a median duration of 468 days (range, 153 - 840 days). Fifteen of these patients received a second injection with satisfactory results obtained in the majority of patients.

Conclusions: Botulinum toxin is an effective treatment for achalasia in about two thirds of patients, with a duration of response averaging 1.3 years. Age and type of achalasia seem to be important predictors of response.

Comment in

Similar articles

See all similar articles

Cited by 85 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback